Clinicians at the University of Pennsylvania have treated two cancer patients with CRISPR, a gene-editing technology that enables precise modifications to DNA.

The patients were treated as part of a recently launched U.S. CRISPR study at the Abramson Cancer Center, a Penn Medicine spokesperson confirmed Tuesday.

One patient has multiple myeloma, a cancer that forms in certain white blood cells. The second patient has sarcoma, a cancer that can occur in the bones and soft tissue.

CRISPR gives scientists the ability to edit DNA more easily, an advantage that could help prevent or treat various diseases.

But the technique has generated ethical concerns given its potential to genetically alter generations to come – particularly after a Chinese doctor controversially used it last year to edit genes in human embryos.

The clinical trial at Penn – and others in the United States – is only focused on treating mutations in adult patients.

Read more at Philly Voice